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70 Poster Session Iinduction/consolidation treatment (n5 3) or as a salvage therapy af-
ter failing multiple prior therapies including autologous SCT (n 5
9). Median number of prior therapy was 4 (range, 2–7). Condition-
ing regimen consisted of fludarabine (180 mg/kg), busulfan (8 mg/
kg), and anti thymocyte globulin. Graft-vs-host disease (GVHD)
prophylaxis consisted of tacrolimus alone.
Results: Median age was 54 years with 50% males. Four patients
had matched unrelated donor (MUD) SCT and 8 had matched sib-
ling SCT. Median CD341 cell dose was 7  106/Kg ideal body
weight. All patients engrafted (with 100% donor chimerism) except
for one patient who died on day 19 due to severe fludarabine neu-
rotoxicity. Three patients never achieved zero absolute granulocyte
count (AGC) and 4 patients did not require platelet transfusions.
Time to AGC . 500 was 18.5 days (n 5 10), and to platelet .
20,000/ul was 12 days (n 5 7). TRM was seen in 3/12 patients
(25%), while 7 patients died of disease progression. The incidence
of grade II-IV acute and extensive chronic GVHD was 45% for
both. Post SCT donor lymphocyte infusions (2–4 infusions) were
used in conjunction with salvage therapy to treat persistent or re-
lapsed MM in 3 patients, all died of progressive disease. Overall re-
sponse rate was 55% with 6 of 11 patients achieving partial
remission or better, and only two patients achieving complete re-
mission. Median progression free and overall survival was 10 and
21.5 months. Currently, 3 patients are alive 31–75 months since
transplant, two of them after MUD SCT, one in complete remis-
sion and the other two with stable residual disease. One patient
never had prior autologous SCT. All three patients have been
treated for mild to moderate extensive chronic GVHD, but no
MM therapy. In conclusion, our results indicate that NMA alloge-
neic SCT is an effective salvage therapy in 25% of patients with ad-
vanced MM, however relapse remains the main reason for failure.PEDIATRIC DISORDERS190
THE EFFECT OF OVERWEIGHT ANDOBESITY ON INTRAVENOUS (IV) BU-
SULFAN METABOLISM IN CHILDREN UNDERGOING REDUCED INTEN-
SITY CONDITIONING (RIC) FOR ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (AHSCT)
Browning, B., Thormann, K., Coyne, K., Kletzel, M. Children’s Memo-
rial Hospital, Chicago, IL.
Pediatric obesity is growing problem in the US. According to the
Centers for Disease Control and Prevention (CDC), 16% of chil-
dren between the ages of 6–19 are considered overweight or obese
with an additional 15% of the pediatric population considered at
risk for becoming overweight. The purpose of this study was to in-
vestigate the predicted versus actual AUC of IV busulfan in children
who are overweight or obese to determine if increased body weight
and adiposity affects the metabolism of this drug.
Retrospective data was collected on 52 pediatric HSCT patients
from 2000–2007 at Children’s Memorial Hospital who underwent
RIC with fludarabine 25 mg/m2/day  5 days and busulfan (single
daily dose) dose adjusted by a test dose  2 days 1/- ATG. Test
dose (TD) of 0.8 mg/kg was given over 2 hrs 5–10 days prior to
stem cell infusion and pharmacokinetic (PK) blood draws were
taken at 4 time points (end of infusion, 30 min., 2, 4 hours post in-
fusion). Regimen doses (RD) were calculated from the AUC and
clearance of the TD and were initiated 5–4 days prior to stem cell
infusion. PK data was collected at 5 time points for the RD (end
of the infusion, 30 min., 2, 5, 24 hours post infusion). All samples
were sent to Seattle Cancer Care Alliance Clinical Pharmacokinet-
ics Laboratory for analysis and calculation of AUC and clearance.
Retrospective data collected included demographics, diagnosis, ht,
wt, calculated BMI, concomitant meds, liver function tests
(LFT’s), TD and RD AUCmMol*min, clearance ml/min/kg and
the dose of BU mg/kg given. Subject were graphed on standard
CDC body mass index (BMI) growth charts then stratified into
BMI categories: \25th%tile, 25–75th%tile, 85–95th%tile and
.95th%tile.
37% of the subjects were overweight or obese. 61% of the sub-
jects reached the targeted AUC with the TD; 80% of the subjects
reached the targeted AUC with the RD. Modifications were madeto the RD in 42 pts. No statistical significance was found between
BMI and TD AUC (p 5 0.31) or RD AUC (p 5 0.96). There was
also no statistical correlation between obtaining targeted TD or
RD AUC and age, sex, LFT’s, concomitant medications, source
of stem cells, diagnosis or weight. It was observed that more TD
and RD AUC anomalies occurred in children who were overweight
or obese. See table. Based on this data, no changes should be made
in current dosing for children who are overweight or obese if the
RD is based on a TD, however, more research with a larger sample
size is warranted.
AUC Trends in each BMI Category
85–95th%tile .95th%tileBMI \25th%tile 25–75th%tile (overweight) (obese)Total Number of Children in
Each Category14 19 9 1027% 37% 17% 19%Test Dose and Regimen Dose
CombinedTotal # of TD or RD AUC’s
\800 and .1200 or\3200 or
.4800 (lower or higher than
predicted)5 9 4 736% 47% 44% 70%Total # of low TD or RD
AUC’s\800 or\3200 (lower
than predicted)5 5 1 136% 26% 11% 10%Total # of high TD and RD
AUC’s .1200 or .4800
(higher than predicted)0 4 3 60% 21% 33% 60%Test DoseTotal # of low TDAUC’s
\800 (lower than predicted)
2 4 0 114% 21% 0% 10%Total # of high TD AUC’s
.1200 (higher than predicted)0 2 3 30% 11% 33% 30%Regimen DoseTotal # of low RD ACU’s
\3200 (lower than predicted)
3 1 1 021% 5% 11% 0%Total # of high RD ACU’s
.4800 (higher than predicted)0 2 0 30% 11% 0% 30%191
ATYPICAL TERATOID/RHABDOID TUMORS: IMPROVED OUTCOME WITH
HIGH-DOSE CHEMOTHERAPY
Schechter, T., Gassas, A., Bartels, U., Doyle, J., Bouffet, E. The Hospital
for Sick Children, Toronto, ON, Canada.
Background: Atypical teratoid/Rhabdoid tumors (ATRT) of the
brain are highly malignant central nervous system (CNS) tumors
which carry a grave prognosis. It comprises up to 15% of malignant
brain tumors. Current treatment recommendations include maxi-
mal surgical resection followed by chemotherapy, with or without
radiation. Despite intensive therapy, the prognosis is poor and the
reported median survival range between 8–17 months; children
younger than 3-yrs of age carry an even worse prognosis. High
dose chemotherapy (HDC) with autologous hematopoietic stem
cell transplant (AHSCT) has been proposed in order to improve
survival. Patients and Methods: A cohort of consecutive children
with ATRT at the Hospital for Sick Children, Toronto, (2000 to
2006). Treatment recommendation during that period was maxi-
mum surgical resection, intensive chemotherapy followed by 3
courses of sequential HDC (with thiotepa and carboplatin) with
AHSCT. Radiation treatment and adjuvant therapy were discussed
case by case. Results: Eight children with ATRT were evaluated in
the study period; 3 patients younger than 1 year with disseminated
disease were not treated. Five patients were treated (demographics,
tumor characteristics, treatment and outcome summarized in the ta-
ble). A total of 15 courses of HDC and AHSCT were performed in 5
patients. There was no treatment related mortality (TRM) follow-
ing HDC; 3 children had febrile neutropenia. Blood cultures in
all episodes were negative. One patient required admission to inten-
sive care unit for a short period. All patients developed mucositis
and were treated with morphine. Engraftment occurred at a mean
